Sarda Proteins board to weigh fund-raise options Aug 5, 2026

What the company has announced

Sarda Proteins Limited has scheduled a meeting of its Board of Directors for Wednesday, August 05, 2026, to consider proposals to raise funds. The company said the board will evaluate multiple routes and instruments, including equity shares and other equity-linked securities. The disclosure was filed with BSE and signed by Managing Director Shirish Dhirajlal Savaliya. The intimation was made under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company’s scrip code on BSE is 519242. The filing was addressed to the General Manager – Listing Compliance at BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001.

Instruments under consideration

The agenda indicates the board will consider raising funds through a broad set of securities. These include equity shares, convertible bonds, debentures, convertible warrants, preference shares, or other equity-linked securities. The presence of convertible instruments suggests the company is keeping flexibility on dilution and cost of capital, depending on the route and terms eventually approved. The proposal, as disclosed, is for consideration by the board and does not specify the size of the fund raise. It also does not disclose pricing, timelines beyond the board meeting date, or the end use of funds. Any eventual issuance would typically require further approvals depending on the structure chosen.

Permissible fund-raising routes cited in the filing

Sarda Proteins has outlined the permissible modes for a capital raise as part of the board’s deliberations. The routes mentioned include rights issue, private placement, preferential issue, and qualified institutions placement (QIP). The company also flagged that the transaction would be evaluated within the framework of applicable laws.

Regulatory framework referenced

The company’s disclosure references the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations). By explicitly citing SEBI ICDR, the filing signals that the company is mapping out options that may involve public market issuances or placements governed by these rules. The board agenda also includes “other business items with the permission of the chairperson,” a standard clause in board meeting notices.

Key agenda items at the August 05, 2026 board meeting

Recent shareholder approvals: name change and authorised capital expansion

The fund-raising proposal comes soon after significant shareholder actions. At an Extra-Ordinary General Meeting (EGM) held on July 30, 2026, shareholders approved a change of the company’s name from Sarda Proteins Limited to Fresita Proteins Limited, subject to statutory and regulatory approvals. At the same EGM, shareholders approved an increase in authorised share capital from ₹13,00,00,000 (₹13 crore) to ₹1,00,00,00,000 (₹100 crore). The resolutions also included consequent alterations to the Memorandum of Association and Articles of Association. In the disclosed details, the board meeting referenced for this decision commenced at 3:00 p.m. and concluded at 5:40 p.m. at the company’s registered office.

Board-level changes and governance actions disclosed in July 2026

In the July 4, 2026 board meeting disclosures, the company noted senior management and board changes. The board approved the resignation of Chirag Shantilal Thumar as Managing Director and the appointment of Shirish Dhirajlal Savaliya as the new Managing Director for a five-year term, subject to shareholder approval. It also recorded that Yagnik Arvindbhai Satasiya’s designation changed from CFO to Additional Director (Non-Executive) and Chairperson. The company appointed Ms. DrashƟ Harshadbhai Delvadiya as the new Chief Financial Officer. The board also noted the resignation of three directors and approved reconstitution of key committees, as per the information provided.

Operational footprint update: corporate office commencement

Separately, Sarda Proteins held a Board of Directors meeting on July 15, 2026. In that meeting, the board considered and approved the establishment and commencement of the company’s Corporate Office with effect from July 15, 2026. The corporate office address disclosed was P-212 B, Gate No. 2, Lodhika GIDC, Rajkot, Metoda, Gujarat, India – 360021. This operational update sits alongside the company’s capital structure decisions and governance changes disclosed in the same month.

A quick timeline of disclosed events

Market context in the disclosures

The documents shared include a historical reference to the company’s share price of ₹130.25 as on September 15, 2025 (04:01 PM IST), along with a note that dividend announcements were not available in the provided data. While the August 2026 board meeting notice focuses on fund-raising options, it does not provide a target amount, issue price, or timetable beyond the meeting date. It also does not specify whether the company will prefer a shareholder-friendly route like a rights issue or a placement-driven route such as a QIP or preferential issue. Any confirmed route and terms would typically be communicated through subsequent exchange filings following board approval.

Why the August 05 board meeting matters

From a corporate actions perspective, the August 05, 2026 meeting is the next step after shareholders approved a larger authorised capital base and a proposed name change. Authorised capital expansion to ₹100 crore increases headroom for issuing additional shares or equity-linked instruments if the board decides to proceed. The presence of multiple instruments and modes in the agenda suggests the company is evaluating flexibility rather than committing to a single financing path at this stage. Investors tracking the stock will likely watch for the post-meeting outcome, including whether the board approves a specific instrument and issuance route under SEBI ICDR and the Companies Act framework.

What to watch next

The immediate next trigger is the board’s decision on August 05, 2026, as and when disclosed to the exchange. If the board approves a fund-raising proposal, further details would typically include the instrument, mode (rights issue, QIP, or otherwise), and any required shareholder or regulatory approvals. Separately, the company’s proposed name change to Fresita Proteins Limited remains subject to statutory and regulatory approvals, as stated in the shareholder resolution.